NEXTBio Capital Management LP Buys Shares of 82,686 Palvella Therapeutics, Inc. $PVLA

NEXTBio Capital Management LP bought a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 4th quarter, Holdings Channel reports. The firm bought 82,686 shares of the company’s stock, valued at approximately $8,655,000. Palvella Therapeutics comprises approximately 5.1% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 7th largest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of PVLA. Millennium Management LLC bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth $7,553,000. Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics in the 1st quarter worth $533,000. Geode Capital Management LLC raised its stake in shares of Palvella Therapeutics by 84.7% in the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after buying an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares in the last quarter. Finally, Rhumbline Advisers bought a new stake in shares of Palvella Therapeutics in the 2nd quarter worth $224,000. Institutional investors own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

PVLA has been the topic of a number of research reports. Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. Mizuho lifted their target price on Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. BTIG Research lifted their target price on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Truist Financial set a $210.00 target price on Palvella Therapeutics in a report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $199.53.

Insider Buying and Selling at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total transaction of $507,592.98. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 20.50% of the company’s stock.

Palvella Therapeutics Trading Up 2.3%

Shares of PVLA stock opened at $108.81 on Friday. Palvella Therapeutics, Inc. has a 1-year low of $20.20 and a 1-year high of $151.18. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -26.09 and a beta of -0.15. The stock’s fifty day simple moving average is $119.52 and its 200-day simple moving average is $108.46.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). On average, sell-side analysts predict that Palvella Therapeutics, Inc. will post -5.26 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.